Fish polar lipids retard atherosclerosis in rabbits by down-regulating PAF biosynthesis and up-regulating PAF catabolism
© Nasopoulou et al; licensee BioMed Central Ltd. 2011
Received: 18 September 2011
Accepted: 16 November 2011
Published: 16 November 2011
Platelet activating factor (PAF) has been proposed as a key factor and initial trigger in atherosclerosis. Recently, a modulation of PAF metabolism by bioactive food constituents has been suggested. In this study we investigated the effect of fish polar lipid consumption on PAF metabolism.
The specific activities of four PAF metabolic enzymes; in leukocytes, platelets and plasma, and PAF concentration; either in blood cells or plasma were determined. Samples were acquired at the beginning and at the end of a previously conducted study in male New Zealand white rabbits that were fed for 45 days with atherogenic diet supplemented (group-B, n = 6) or not (group-A, n = 6) with gilthead sea bream (Sparus aurata) polar lipids.
The specific activity of PAF-Acetylhydrolase (PAF-AH); a catabolic enzyme of PAF, was decreased in rabbits' platelets of both A and B groups and in rabbits' leukocytes of group A (p < 0.05). On the other hand the specific activity of Lipoprotein-associated Phospholipase A2 (Lp-PLA2); the catabolic enzyme of PAF in plasma was increased in both A and B groups in both leukocytes and platelets (p < 0.05). PAF-cholinephosphotransferase (PAF-CPT); a biosynthetic enzyme of PAF showed increased specific activity only in rabbits' leukocytes of group A (p < 0.05). Neither of the two groups showed any change in Lyso-PAF-acetyltransferase (Lyso-PAF-AT) specific activity (p > 0.05). Free and bound PAF levels increased in group A while decreased in group B (p < 0.05).
Gilthead sea bream (Sparus aurata) polar lipids modulate PAF metabolism upon atherosclerotic conditions in rabbits leading to lower PAF levels and activity in blood of rabbits with reduced early atherosclerotic lesions compared to control group.
KeywordsFish polar lipids Mediterranean Diet Cholesterol; Platelet Activating Factor (PAF) PAF Enzymes Atherosclerosis
Platelet Activating Factor (PAF)  has been proposed as key factor in atherosclerosis development . Dysregulation of PAF metabolism, lead to increased PAF-levels and triggers local inflammatory response onto the endothelium of arteries  with prominent role in atherogenesis [3, 4].
The biosynthesis of PAF is accomplished through two distinctive enzymatic pathways; the de novo pathway; catalyzed by a specific dithiothreitol-insensitive CDP-choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase (PAF-cholinephosphotransferase; PAF-CPT, EC 184.108.40.206) that converts 1-O-alkyl-2-acetyl-glycerol to PAF and the remodeling one; catalyzed by lyso-PAF:acetyl-CoA acetyltransferase (Lyso-PAF-acetyltransferase; Lyso-PAF-AT, EC 220.127.116.11)  which acetylates lyso-PAF. On the other hand the catabolism of PAF in blood is catalyzed by a PAF-specific acetylhydrolase (PAF-AH, EC 18.104.22.168) whose plasma form is known as Lipoprotein-associated phospholipase A2 (Lp-PLA2) . PAF-AH cleaves short chain acyl chains at the sn-2 position of phospholipids such as, oxidized phospholipids and PAF.
Various foodstuffs contain molecules that inhibit in vitro the activity of PAF . Many micro- and macro-nutrients of the Mediterranean diet slow down the development of atherosclerosis [2, 7]. In previous studies we have published that lipid minor constituents that inhibit in vitro PAF-induced thrombosis have been isolated from milk and yogurt, red and white wine and must, seed oils, olive oil, olive pomace and fish . Recently we have published that supplementation of polar lipids from cultured gilthead sea bream (Sparus aurata) (GSBPL) inhibit early atherosclerosis development in diet induced hypercholesterolemic rabbits .
The aim of the study was to investigate how the consumption of GSBPL affects the enzyme activities of PAF metabolism and PAF levels in rabbits' blood cells and plasma upon atherosclerotic conditions.
Isolation of fish polar lipids
Gilthead sea bream polar lipids (GSBPL) constituted the 0.23% of the whole fresh fish weight, since an amount of 28.0 g of polar lipids were isolated from 12.0 kg of cultured gilthead sea bream (S. aurata).
Liquid chromatographic analysis
The fraction of GSBPL that was eluted at 95-105 min upon HPLC separation exerted antagonistic effect against PAF toward washed rabbit platelets (data not shown) and in an effort to characterize qualitatively this fraction phosphorus and sugar determinations were performed. Phosphorus determination in this fraction was negative whereas sugar determination was positive giving 50.44 mmol of sugars per mg of fish polar lipid fraction expressed as glucose.
Gas chromatographic analysis
Gas chromatographic analysis of fatty acids in Gilthead Sea Bream Polar Lipids (GSBPL).
17.0 ± 3.40
419 ± 83.9a
30.6 ± 6.12
99.8 ± 20.0
18:1 cis (omega-9)
155 ± 77.7a
18:1 trans (omega-9)
29.4 ± 5.88
62.1 ± 12.4
18.8 ± 3.77
152 ± 30.6a
26.7 ± 5.33
405 ± 80.9a
PAF-basic metabolic enzyme specific activities
The PAF-metabolic specific enzyme activities of the two experimental groups A and B at the beginning and at the end of the experimental diet are presented in Table 2. Specific enzyme activities and PAF levels of both A and B groups were comparable at the beginning of the study (p > 0.05). In group A, specific activity of PAF-CPT in leukocytes was significantly increased after 45 days on atherogenic diet compared to baseline (p < 0.05). In contrast, in group B PAF-CPT specific activity in Leukocytes did not change compared to its initial values. The increase of PAF-CPT specific activity in group A resulted in higher values in group A compared to group B at the end of the study (p < 0.05). The specific activity of PAF-CPT in platelets of group A, unlike of its activity in leukocytes, was comparable to its initial values after 45 days. On the other hand PAF-CPT specific activity in platelets of group B was significantly decreased (p < 0.05), but values of PAF-CPT specific activity of both A and B groups at the end of the study were not statistically different.
The specific activity of Lyso-PAF-AT in leukocytes in both A and B groups were not statistically different at the end of the study compared to baseline. The increase of Lyso-PAF-AT activity in leukocytes of group A failed to reach statistical significance, but after 45 days this activity was higher compared to that of group B (p < 0.05). In platelets of group A the specific activity of Lyso-PAF-AT was not statistically different after 45 days, whereas in platelets of group B, this enzyme activity was significantly reduced (p < 0.05) but values between A and B groups at 45 days were not statistical different.
PAF metabolic enzyme specific activities in plasma, leukocytes and platelets along with PAF levels in rabbit blood upon experimental diet.
A (n = 6)
B(n = 6)
PAF-CPT specific activity in Leukocytes
(nmol PAF/min/mg protein)
0.85 ± 0.29
0.57 ± 0.36
2.52 ± 0.81a
0.66 ± 0.51b
PAF-CPT specific activity in platelets
(nmol PAF/min/mg protein)
2.04 ± 1.11
1.49 ± 0.80
1.89 ± 1.30
0.49 ± 0.31a
Lyso PAF AT specific activity in Leukocytes
(nmol PAF/min/mg protein)
0.0545 ± 0.0427
0.0200 ± 0.0149
0.1102 ± 0.0517
0.0256 ± 0.0239b
Lyso PAF AT specific activity in platelets
(nmol PAF/min/mg protein)
0.0047 ± 0.0023
0.0042 ± 0.0030
0.0029 ± 0.0022
0.0011 ± 0.0006a
PAFAH specific activity in Leukocytes
(nmol PAF/min/mg protein)
340 ± 61.3
273 ± 109
163 ± 15.7a
581 ± 340b
PAFAH specific activity in Platelets
(nmol PAF/min/mg protein)
96.5 ± 30.4
112 ± 20.2
25.0 ± 7.62a
30.8 ± 10.7a
Lp-PLA2 specific activity in plasma
(pmol PAF/min/μL PPP)
128 ± 35.3
109 ± 15.2
174 ± 21.6a
239 ± 56.7a
PAF levels in plasma; Free PAF levels
3.1 ± 1.7
3.04 ± 1.23
5.0 ± 1.8a
0.24 ± 0.12a,b
PAF levels in cells; Bound PAF levels
0.88 ± 0.15
1.08 ± 0.36
1.8 ± 0.34a
0.18 ± 0.08a,b
PAF levels in rabbits' blood
Free and bound PAF levels in both A and B groups were comparable at the beginning of the study (p > 0.05). At the end of the study both free and bound PAF levels were statistically higher in group A (p < 0.05) and lower in group B (p < 0.05) compared to the initial values, leading to higher values in group A compared to group B (p < 0,05) (Table 2).
Atherosclerosis still remains a leading cause of morbidity and mortality world-wide. PAF and its metabolism have been proposed as key factors in atherosclerosis development [2–4, 9]. In a research effort it has been shown that many food-derived bioactive compounds alter the metabolism and/or the activity of inflammatory mediators like PAF both in in vitro and in vivo experiments, contributing in a favorable clinical profile when consumed in the diet .
Epidemiological and clinical trials have shown a beneficial effect of fish consumption toward cardiovascular diseases [10–12], attributed mainly to omega-3 fatty acids [12–14]. However, recently we showed that beyond omega-3 fatty acids, the consumption of GSBPL led to an inhibition of early atherosclerosis development in diet induced hypercholesterolemic rabbits . In the present study whole blood, plasma, leukocytes and platelets of that previously conducted study  were used in order to investigate how the consumption of GSBPL upon atherosclrerotic conditions affect the activities of PAF metabolic enzymes and PAF levels in rabbits. Leukocytes and platelets were chosen for this study due to their critical role in the onset of atherosclerosis [2, 15, 16].
The low content of cultured gilthead sea bream (Sparus aurata) in polar lipids (0.23% of the whole fresh fish weight) indicates their high antiatherogenic activities since a 75% retardation of early atherosclerosis development has been observed compared to control group as a result of 133 mg consumption of GSBPL per rabbit per day as noted previously . Moreover, HPLC chromatographic behavior, chemical determinations and fatty acid analysis in GSBPL shows that the bioactive polar lipids are peculiar glycolipids rather than classic phospholipids with palmitic, docosahexaenoic (DHA), oleic and eicosapentaenoic (EPA) fatty acids mainly esterified in their structures.
In the present study leukocytes and platelets in rabbits upon atherosclerotic conditions have been shown to contribute to an increased PAF biosynthesis. The increased PAF biosynthesis in group A comes from an increased activity of PAF-CPT in leukocytes along with a decreased activity of PAF-AH in both leucocytes and platelets. The increased de novo biosynthesis and the decreased catabolism of PAF in leukocytes and platelets are in accordance with the elevated PAF levels in both plasma (free PAF) and cells (bound PAF). These results are paralleled with both the formation of early atherosclerosis lesions and the increased aggregatory response of platelets toward PAF; expressed as reduced EC50 that had been previously observed in group, which was not administered with fish polar lipids . These observations are in accordance with the fact that, on one hand, elevated PAF levels can trigger platelet stimulation and local inflammatory response onto endothelium [2, 4, 17], while, on the other hand, PAF-CPT activity in leukocytes is positively correlated with increased inflammation .
Atherogenic diet supplemented with GSBPL in group B has previously shown statistically significant lower early atherosclerotic lesions compared to group A . In the present study, this effect was paralleled by a modulation in PAF metabolism in leukocytes and platelets of group B compared to that of group A. In contrast to group A, PAF-CPT in leukocytes of group B ceases further increase upon atherosclerotic conditions. Moreover a decrease of both PAF-CPT and Lyso PAF-AT activities were shown in platelets of group B. As a response of reduced PAF biosynthesis in platelets, platelet PAF-AH was also decreased; an observation consistent with data indicating that intracellular PAF acetylhydrolase activity is a critical component of stimulated PAF production . The reduced PAF levels in both plasma and cells are in accordance with the observed reduction of PAF biosynthetic enzymes activities in platelets and the increased activity of Lp-PLA2 in plasma. These observations are also in agreement with the previous notion that platelets are less sensitive to aggregation towards PAF in group administered with fish polar lipids, where increased EC50 values were observed . The increased activity of Lp-PLA2 in plasma of both A and B group showed a response of this enzyme towards atherogenic conditions independently of the GSBPL co-supplementation that cannot be predicted only by PAF metabolism modulation in leukocytes and platelets.
We found that GSBPL modulate PAF metabolic enzymes upon atherosclerosis in a way that PAF levels are maintained low. The modulation of PAF metabolic enzyme activities leads to reduced platelet aggregatory response toward PAF and reduced early atherosclerotic lesions in group consumed GSBPL . The appreciation of the role of PAF and its metabolism in atherosclerosis provides a mechanistic framework for understanding and unravelling mechanisms where bioactive food micronutrients are implicated in atherogenesis prevention.
Materials and methods
1-O-hexadecyl-2-[3H] acetyl-sn-glycerol-3-phosphocholine ([3H]-PAF) with a specific activity of 10 Ci/mmol was obtained from New England Nuclear & Dupont (Boston, MA, USA). 1-O-alkyl-2-sn-acetyl-glycerol (AAG) was purchased from BIOMOL International LP (Exeter, UK). Both 2,5-Diphenyloxazole (PPO) and 1,4-bis(5-phenyl-2-oxazolyl) benzene (POPOP) were purchased from BDH Chemicals (Dorset, UK). Liquid chromatography grade solvents and silica G for TLC were purchased from Merck (Darmstadt, Germany). All the rest analytical reagents and solvents were purchased from Sigma (St.Louis, MO, USA).
We performed HPLC analysis on a Hewlett-Packard series 1100 (Avondale, PA, USA), equipped with a G1314A HP UV spectrophotometer. A normal phase YMC-Pack HPLC column with amino functional groups 250 × 20 mm, S-5 μm (Whatman, Maidstone, UK) was used for the chromatographic profile of fish polar lipids, while a cation exchange column SCX Partisil HPLC column 250 × 4.6 mm, 10 μm (Whatman (Maidstone, UK) was used for PAF isolation.
We performed GC analysis on a Shimadzu CLASS-VP (GC-17A) gas chromatograph (Kyoto, Japan), equipped with a split/splitless injector, flame ionization detector and an Agilent J&W DB-23 fused silica capillary column 60 m × 0.251 mm, 0.25 μm, (Santa Clara, CA, USA).
Homogenizations were conducted at 40KHz with a VC50 supersonic sonicator (Newtown, CT, USA). The liquid scintillation counter used was a 1209 Rackbeta (Pharmacia, Wallac, Finland). PAF-induced platelet aggregation studies were performed in a model 400 VS aggregometer of Chrono-Log (Havertown, PA, USA) coupled to a Chrono-Log recorder at 37°C with constant stirring at 1200 rpm.
Isolation of fish polar lipids
Fish polar lipids were extracted from cultured gilthead sea bream (S. aurata) cultivated in Nireus Aquaculture S.A., situated in Chios Island, Greece. Total lipids were extracted according to the Bligh-Dyer method  and were further separated into polar and neutral lipids by counter-current distribution . GSBPL were stored at -20°C until further analysis.
Chemical determinations in fish polar lipids
Fish polar lipid chromatographic profile
We acquired fish polar lipid chromatographic profile by HPLC on an amino functional group HPLC column using a modified previously described elution system .
Gas Chromatographic analysis of fish polar lipids Fatty acids
We prepared fatty acid methyl esters of GSBPL using a solution 0.5N KOH in 90% aqueous CH3OH and then we extracted them by n-hexane. The fatty acid analysis was carried out using the internal standard method as previously described .
At the beginning and after 45 days, of a previously conducted study , we collected blood from twelve male New Zealand white rabbits and we determined PAF-levels and isolated leukocytes, platelets and plasma where we determined the specific activities of the four PAF-basic metabolic enzymes; PAF-CPT, Lyso-PAF-AT, PAF-AH and Lp-PLA2. Animal handling and treatment have been conducted as previously described . In that study, twelve male New Zealand white rabbits of same weight and age were randomly divided into two groups of six animals each and were given specific diets for 45 days. Group A was the control group and was given typical diet supplemented with 1% cholesterol as atherogenic diet, while Group B was given atherogenic diet enriched with 0.06% (w/w) GSBPL. The research protocols of the study have been performed with the approval of local veterinary authorities and animal ethics committee.
Isolation of plasma, leukocytes and platelets from blood of rabbits
An amount of 9.0 mL of blood from hypercholesterolemic rabbits was obtained from each rabbit in 1.0 mL of an anticoagulant solution of 0.085 M sodium citrate/0.065 M citric acid, at the beginning (0 days) and at the end (45 days) of the study where isolation of plasma, leukocytes and platelets were performed as previously described . In each case protein was determined according to the method of Bradford  with BSA as the protein standard.
Determination of PAF-basic metabolic enzyme specific activities
We determined PAF metabolic enzyme specific activities in triplicate in aliquots of leukocyte and platelet homogenates or plasma prepared from blood of hypercholesterolemic rabbits taken at 0 and 45 days. PAF-CPT and Lyso-PAF-AT specific activities were determined as previously described [26, 28]. Specific enzymes activities of PAF-CPT and Lyso-PAF-AT were expressed as nmol of produced PAF/min/mg of sample protein present in each assay. Specific activities of intracellular PAF-AH and Lp-PLA2 were determined as previously described by the TCA precipitation method . We used aliquots of 2.0 μL of plasma to determine Lp-PLA2 specific activity and aliquots of leukocytes and platelet homogenates with a final concentration of 0.5 mg protein per mL per assay to determine PAF-CPT, Lyso-PAF-AT and intracellular PAF-AH specific activities.
Determination of PAF levels in rabbit blood
Normality of the data was examined by the Kolmogorov-Smirnov criterion before further analysis. Differences in enzyme specific activities and PAF levels within each group and between group A and B were conducted using the paired t-test and one way ANOVA test respectively. Data considered being statistically significant when p value was found below 0.05. The data were analyzed using a statistical software package (PASW 18 for Windows, SPSS Inc., Chicago, IL, USA).
Platelet Acticating Factor
Lipoprotein associated phospholipase A2
gilthead sea bream polar lipids
(1) The present research was partially supported by the State Scholarships Foundation of Greece - SSFG - (Dr AB Tsoupras holds a SSFG post-doctoral scholarship in Biochemistry).
(2) We would like to thank the aquaculture company NIREUS S.A. for their kindly donation of fish samples.
(3) Part of this work was presented in the 4th Greek conference of Atherosclerosis, Ioannina, Greece, October 2010.
- Demopoulos CA, Pinckard RN, Hanahan DJ: Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979, 254: 9355-9358.PubMedGoogle Scholar
- Demopoulos CA, Karantonis HC, Antonopoulou S: Platelet activating factor - A molecular link between atherosclerosis theories. Eur J Lipid Sci Tech. 2003, 105: 705-716. 10.1002/ejlt.200300845.View ArticleGoogle Scholar
- Libby P: Inflammation in atherosclerosis. Nature. 2002, 420: 868-874. 10.1038/nature01323View ArticlePubMedGoogle Scholar
- Ninio E: Phospholipid mediators in the vessel wall: involvement in atherosclerosis. Curr Opin Clin Nutr Metab Care. 2005, 8: 123-131. 10.1097/00075197-200503000-00004View ArticlePubMedGoogle Scholar
- Nomikos T, Fragopoulou E, Antonopoulou S: Food ingredients and lipid mediators. Curr Nutr Food Sci. 2007, 3: 255-276.View ArticleGoogle Scholar
- Stafforini DM: Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2. Cardiovasc Drugs Ther. 2009, 23: 73-83. 10.1007/s10557-008-6133-8View ArticlePubMedGoogle Scholar
- Lorgeril M, Salen P: The mediterranean diet: Rationale and evidence for its benefit. Curr Atheroscler Rep. 2008, 10: 518-522. 10.1007/s11883-008-0080-5View ArticlePubMedGoogle Scholar
- Nasopoulou C, Karantonis HC, Perrea DN, Theocharis SE, Iliopoulos DG, Demopoulos CA, Zabetakis I: In vivo anti-atherogenic properties of cultured gilthead sea bream (Sparus aurata) polar lipid extracts in hypercholesterolaemic rabbits. Food Chem. 2010, 120: 831-836. 10.1016/j.foodchem.2009.11.023.View ArticleGoogle Scholar
- Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM: The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002, 30 (Suppl 5): 294-301.View ArticleGoogle Scholar
- Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB: Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997, 336: 1046-1053. 10.1056/NEJM199704103361502View ArticlePubMedGoogle Scholar
- Zhang J, Sasaki S, Amano K, Kesteloot H: Fish consumption and mortality from all causes, ischemic heart disease, and stroke: An ecological study. Prev Med. 1999, 28: 520-529. 10.1006/pmed.1998.0472View ArticlePubMedGoogle Scholar
- Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002, 106: 2747-2757. 10.1161/01.CIR.0000038493.65177.94View ArticlePubMedGoogle Scholar
- Bucher HC, Hengstler P, Schindler C, Meier G: N-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials. Am J Med. 2002, 112: 298-304. 10.1016/S0002-9343(01)01114-7View ArticlePubMedGoogle Scholar
- Din JN, Newby DE, Flapan AD: Omega 3 fatty acids and cardiovascular disease - Fishing for a natural treatment. BMJ. 2004, 328: 30-35. 10.1136/bmj.328.7430.30PubMed CentralView ArticlePubMedGoogle Scholar
- Li N, Hu H, Lindqvist M, Wikström-Jonsson E, Goodall AH, Hjemdahl P: Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol. 2000, 20: 2702-2708. 10.1161/01.ATV.20.12.2702View ArticlePubMedGoogle Scholar
- Das UN: Cross talk among leukocytes, platelets, and endothelial cells and its relevance to atherosclerosis and coronary heart disease. Curr Nutr Food Sci. 2009, 5: 75-93. 10.2174/157340109788185599. 10.2174/157340109788185599View ArticleGoogle Scholar
- Shi G, Morrell CN: Platelets as initiators and mediators of inflammation at the vessel wall. Thromb Res. 2011, 127: 387-390. 10.1016/j.thromres.2010.10.019PubMed CentralView ArticlePubMedGoogle Scholar
- Detopoulou P, Nomikos T, Fragopoulou E, Antonopoulou S, Kotroyiannis I, Vassiliadou C, Panagiotakos DB, Chrysohoou C, Pitsavos C, Stefanadis C: Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Clin Biochem. 2009, 42: 44-49. 10.1016/j.clinbiochem.2008.09.113View ArticlePubMedGoogle Scholar
- Chen J, Yang L, Foulks JM, Weyrich AS, Marathe GK, McIntyre TM: Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF synthesis. J Lipid Res. 2007, 48: 2365-2376. 10.1194/jlr.M700325-JLR200View ArticlePubMedGoogle Scholar
- Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959, 37: 911-917. 10.1139/o59-099View ArticlePubMedGoogle Scholar
- Galanos DS, Kapoulas VM: Isolation of polar lipids from triglyceride mixtures. J Lipid Res. 1962, 3: 134-137.Google Scholar
- Bartlett GR: Phosphorus assay in column chromatography. J Biol Chem. 1959, 234: 466-468.PubMedGoogle Scholar
- Galanos DS, Kapoulas VM: Preparation and analysis of lipid extracts from milk and other tissues. Biochim Biophys Acta. 1965, 98: 278-292.View ArticlePubMedGoogle Scholar
- Nomikos T, Karantonis HC, Fragopoulou E, Demopoulos CA: One-step separation system for the main phospholipids, glycolipids, and phenolics by normal phase HPLC. Application to polar lipid extracts from olive and sunflower oils. J Liq Chromatogr Relat Technol. 2002, 25: 137-149. 10.1081/JLC-100108545.View ArticleGoogle Scholar
- Nasopoulou C, Stamatakis G, Demopoulos CA, Zabetakis I: Effects of olive pomace and olive pomace oil on growth performance, fatty acid composition and cardio protective properties of gilthead sea bream (Sparus aurata) and sea bass (Dicentrarchus labrax). Food Chem. 2011, 129: 1108-1113. 10.1016/j.foodchem.2011.05.086.View ArticlePubMedGoogle Scholar
- Tsoupras AB, Chini M, Tsogas N, Fragopoulou E, Nomikos T, Lioni A, Mangafas N, Demopoulos CA, Antonopoulou S, Lazanas MC: Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?. AIDS Res Hum Retroviruses. 2008, 24: 1079-1086. 10.1089/aid.2007.0263View ArticlePubMedGoogle Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3View ArticlePubMedGoogle Scholar
- Tsoupras AB, Fragopoulou E, Nomikos T, Iatrou C, Antonopoulou S, Demopoulos CA: Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflamm. 2007, 2007: 27683-PubMed CentralView ArticlePubMedGoogle Scholar
- Iatrou C, Moustakas G, Antonopoulou S, Demopoulos CA, Ziroyiannis P: Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis. Nephron. 1996, 72: 611-616. 10.1159/000188948View ArticlePubMedGoogle Scholar
- Demopoulos CA, Andrikopoulos NK, Antonopoulou S: A simple and precise method for the routine determination of platelet-activating factor in blood and urine. Lipids. 1994, 29: 305-309. 10.1007/BF02536336View ArticlePubMedGoogle Scholar
- Andrikopoulos NK, Demopoulos CA, Siafaka-Kapadai A: High-performance liquid chromatographic analysis of platelet activating factor on a cation-exchange column by direct ultraviolet detection. J Chromatogr A. 1986, 363: 412-417. 10.1016/S0021-9673(01)83766-3.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.